首页> 外国专利> COMPOSITIONS OF ENDODERM CELLS AND HEPATIC PARENCHYMAL CELLS AND METHODS FOR OBTAINING AND USING THESE CELLS

COMPOSITIONS OF ENDODERM CELLS AND HEPATIC PARENCHYMAL CELLS AND METHODS FOR OBTAINING AND USING THESE CELLS

机译:内胚层细胞和肝性肝癌细胞的组成以及获得和使用这些细胞的方法

摘要

PROBLEM TO BE SOLVED: To provide efficient methods for generating a population of endoderm cells and/or differentiated cells derived from endoderm cells such as hepatic cells, pancreatic progenitor cells, pancreatic cells, intestinal progenitor cells, intestinal cells, lung progenitor cells and lung cells.;SOLUTION: Provided is an isolated population of endoderm cells at least 83% of which are expressing SOX17, at least 77% of which are expressing FoxA2 or at least 76% of which are expressing CXCR4. Also provided is a method for culturing the endoderm cells in a culture medium containing an effective amount of a selective inhibitor of P13Kα and an effective amount of Activin A. The selective inhibitor of P13Kα may be a fused pyrimidine compound of Formula (I), specifically preferable one may be 4-[2-(1H-indazole-4-yl)-6-[(4-methylsulfonyl piperazine-1-yl)methyl]thieno[3,2-d)pyrimidine-4-yl]morpholine.;SELECTED DRAWING: None;COPYRIGHT: (C)2017,JPO&INPIT
机译:要解决的问题:提供有效的方法来生成内胚层细胞和/或源自内胚层细胞的分化细胞,例如肝细胞,胰腺祖细胞,胰腺细胞,肠祖细胞,肠细胞,肺祖细胞和肺细胞解决方案:提供的分离的内胚层细胞群至少有83%表达SOX17,其中至少77%表达FoxA2或至少76%表达CXCR4。还提供了在含有有效量的P13Kα选择性抑制剂和有效量的激活素A的培养基中培养内胚层细胞的方法。P13Kα的选择性抑制剂可以是式(I)的稠合嘧啶化合物。优选的是4- [2-(1H-吲唑-4-基)-6-[(4-甲基磺酰基哌嗪-1-基)甲基]噻吩并[3,2-d)嘧啶-4-基]吗啉。 ;选定的图纸:无;版权所有:(C)2017,JPO&INPIT

著录项

  • 公开/公告号JP2017113005A

    专利类型

  • 公开/公告日2017-06-29

    原文格式PDF

  • 申请/专利权人 F. HOFFMANN-LA ROCHE AG;

    申请/专利号JP20170009924

  • 发明设计人 ESTELLE DOUDEMENT;HIRDESH UPPAL;

    申请日2017-01-24

  • 分类号C12N5/071;C12Q1/04;A61K35/39;A61K35/407;A61P1/16;A61P1/18;A61P1;A61P1/04;A61P35;A61P43;

  • 国家 JP

  • 入库时间 2022-08-21 13:59:07

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号